Jerome B. Zeldis is the EVP for R&D at NexImmune. Prior to this role, he was the Executive Chairman of ViralClear, subsidiary of BioSig Corporation. He founded the company to develop an antiviral drug to COVID-19. Previously, he was the Chief Medical Officer and President of Clinical Research, Regulatory, and Safety at Sorrento Therapeutics.

He was CEO of Celgene Global Health and Chief Medical Officer of Celgene Corporation, Summit, NJ. Prior to that he was Celgene’s Senior Vice President of Clinical Research and Medical Affairs and has been at Celgene since February, 1997. He attended Brown University for an A.B., M.S., followed by Yale University for an M.Phil., M.D., Ph.D. in Molecular Biophysics and Biochemistry (immunochemistry). Dr. Zeldis trained in Internal Medicine at the UCLA Center for the Health Sciences and Gastroenterology at the Massachusetts General Hospital and Harvard Medical School. He was Assistant Professor of Medicine at the Harvard Medical School, Associate Professor of Medicine at University of California, Davis, Clinical Associate Professor of Medicine at Cornell Medical School and Professor of Clinical Medicine at the Robert Wood Johnson Medical School in New Brunswick, New Jersey. Prior to working at Celgene, Dr. Zeldis worked at Sandoz Research Institute and Janssen Research Institute in both clinical research and medical development. He has been a board member of a few start-up biotechnology companies and is currently on the board of the Semorex Corporation, PTC Corporation, Soligenix, Trek Therapeutics and BionorPharma. He has published 122 peer reviewed articles and holds 43 US patents.